An Observational, Longitudinal Study to Describe the Outcome and Predictors in Patients With Primary Membranous Nephropathy and Nephrotic Syndrome Treated With Rituximab or Other Monoclonal Antibodies

What this Trial Is About

Researchers are tracking the course of primary membranous nephropathy (PMN), a rare autoimmune kidney disease that causes nephrotic syndrome in adults. The study focuses on understanding long-term outcomes for patients in real-world clinical practice, especially in light of new treatment options such as monoclonal antibodies. The goal is to gain insights into disease progression and response to these therapies over time. Participants will be observed without any experimental treatment assigned by the study. The focus is on patients diagnosed with PMN and nephrotic syndrome who have been treated with rituximab or other monoclonal antibodies as part of their care. Researchers will collect data from routine clinical visits and follow patients longitudinally to capture disease remission, progression, and treatment effects. During the study, participants will provide consent for their medical data to be used for research. Researchers will monitor disease remission and progression, kidney function decline, blood parameters, and any adverse events related to treatment throughout the study, which typically spans about six months on average. The study will help understand outcomes and predictors in patients managed with current therapies and support better future care.

An Outcome Analysis of Primary Membranous Nephropathy